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Abstract The economic benefits of
daily migraine prevention have
been subject to ongoing debate.
This study was undertaken to
determine if the initiation of pre-
vention had an observable effect
on ambulatory health care utilisa-
tion when compared to acute
migraine treatment alone.
Administrative claims data from
the Military Health System were
used to conduct a retrospective,
longitudinal cohort study of 3762
patients with migraine. New users
of daily migraine prevention were
matched to a reference group of
non-users using propensity score
methods. This matched sample
then was used to evaluate the
effect of prevention on ambulatory
health care expenditures. The
study results showed that exposure
to daily migraine prevention led to
lower rates of utilisation relative to
what new patients would have con-
sumed in the absence of treatment.
The results suggest that additional
economic benefits could be
realised by increasing the appro-
priate use of daily migraine pre-
vention. 
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Introduction
Migraine is a widespread and disabling neurological dis-
order that presents a formidable challenge to health care
providers [1]. The economic consequences of the disease
are considerable, placing a significant burden on patients,
health plans and employers worldwide [2–6]. Individuals
that receive treatment for migraine generally consume
more health care resources than patients without the con-
dition [7]. Moreover, migraine headaches are a significant
source of patient disability [2–6, 8, 9]. This disability has
in turn been linked to reduced productivity during
arguably the most productive years of a person’s life [10,
11]. As such, treatments that enhance the management of
migraine in a safe and cost-effective manner should be a
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priority for health care organisations.
Over the last decade, several advances have enhanced
the ability to manage patients who suffer from migraine.
One such breakthrough was the expansion of effective
choices for daily migraine prevention. While prevention
has been shown to reduce the frequency and severity of
migraine headaches [12, 13], it is unclear whether or not
this treatment has an effect on a patient’s use of migraine-
related medical services. Cost-effectiveness analysis has
suggested that some preventive medications are cost-
effective, but for only a subset of patients with frequent
headaches or comorbid illness [14, 15]. Because tradition-
al economic evaluations are typically based on efficacy
data from clinical trials, the results may not be readily
transferable to routine medical practice. As a result, health
researchers are more frequently relying on analyses of
administrative claims data to compare direct health care
expenditures for patients exposed to different treatments
in an effort to gauge economic benefits [16].
Two studies of this type recently have examined the
relationship between migraine prevention and health care
resource utilisation [17, 18]. The results suggest that the
addition of a preventive medication to an individual’s
existing treatment for migraine reduced utilisation of
abortive prescription medications, physician visits and
emergency room visits which resulted in overall cost-sav-
ings to the health plans. However, the results were criti-
cised because of methodological shortcomings in design
and implementation of the analysis [19]. In this paper, we
build on previous research [17, 18] and attempt to address
several threats to validity identified in earlier studies. Our
objective is to evaluate if initiation of daily migraine pre-
vention has an observable affect on ambulatory health care
utilisation compared to acute migraine treatment alone. 
Materials and methods
Source of data
We conducted a retrospective longitudinal analysis of pharmacy
and medical claims data among beneficiaries suffering from
migraine in the US Military Health System (MHS). The data were
collected from TRICARE, the health insurance coverage program
for the MHS, which covers care provided at military medical
facilities and also pays for contracted medical care from the pri-
vate sector across the USA [20]. Programme beneficiaries include
active duty and retired members of the uniformed services in the
USA, their family members and survivors. Two years of data
were available for the analysis beginning 1 October 2002 and
ending 30 September 2004. All research was performed in accor-
dance with appropriate ethical standards and the study protocol
was approved by the Institutional Review Board at the University
of Minnesota.
Study population
The initial migraine population was selected based on documen-
tation of headache-related pharmacy and medical encounters that
occurred during the study timeline. The initial study population
included patients who met each of the following criteria: (1)
received a prescription for a migraine-specific abortive medica-
tion (MSAM) (described below) during the six-month window
of 1 April 2003 to 30 September 2003 (the date of the first pre-
scription during this period was labelled as that patient’s index
date); (2) experienced an ambulatory health care encounter with
an ICD-9-CM code 346.XX (migraine) between 1 October 2002
and 30 September 2004; (3) between 17 and 64 years of age on
the index date; and (4) eligible for care during the study period.
If patients did not meet all four criteria, they were excluded from
the initial migraine study population.
A MSAM mentioned above was defined as a claim for sero-
tonin receptor agonist (e.g., sumatriptan), an ergotamine deriva-
tive or an isometheptene-containing product. All MSAMs are
indicated primarily for the acute treatment of migraine headache.
The abortive medications do not possess any common off-label
indications, which minimised the possibility of misclassification
bias (i.e., detection of patients who do not suffer from migraine
but are receiving treatment with MSAM). Furthermore, identifi-
cation of patients using the inclusion criteria above was recently
reported to be an effective method for claims-based recognition
of migraine patients in a managed care population [21].
Conceptual framework
Several areas of previous research helped develop the conceptu-
al framework for this study. Aspects of the design were based on
the Economic, Clinical, and Humanistic Outcomes (ECHO)
model [22], originally developed to assist researchers in the
examination of causal relationships between pharmaceutical
treatments and health outcomes. The Behavioural Model of
Health Care Utilisation [23] was incorporated to help identify
the determinants of health care utilisation. The model charac-
terises health care utilisation as a function of three categories:
(1) predisposing characteristics (e.g., age or gender); (2)
enabling characteristics (e.g., insurance status); or (3) need char-
acteristics (e.g., headache frequency or severity). The model was
useful because it provided a theoretical framework to identify
important explanatory variables in a patient’s decision to utilise
health resources.
Dependent variable
The dependent variable measured TRICARE spending for
migraine-related outpatient services. Each subject’s spending
was categorised as prescription, non-emergent ambulatory care
or emergency room care, with the sum of all three equal to total
outpatient spending for migraine-related care. Prescription
spending included the costs of all dispensed medications identi-
fied as either definitely (e.g., MSAM) or potentially (e.g., non-
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steroidal anti-inflammatories or anti-emetics) related to
migraine. This classification has been used previously in
migraine research [24] and a complete list of the medications in
each category is available from the authors upon request.
Spending for migraine-related medical care was derived from
claims with a migraine ICD-9-CM diagnosis code (346.XX).
Each subject’s spending was measured separately during
three 180-day intervals determined from the index date (Fig. 1).
The 180-day intervals surrounded the index date with one imme-
diately preceding it and two following the index date. The inter-
vals were referred to as pre-treatment, transitional and post-
treatment respectively. Use of 180-day intervals allowed for a
standardised comparison of the study outcome measures before
and after the index date for each study subject. The primary
study endpoints for each category were (1) post-treatment spend-
ing and (2) the change in spending from the transitional interval
to the post-treatment interval (calculated as the difference
between the post-treatment and transitional intervals).
Explanatory variables
The independent variable of interest was a dichotomous measure
of whether or not an individual was exposed to daily migraine
prevention. For the purposes of this study, exposure to preven-
tion was defined as a prescription for either (1) a migraine pre-
ventive medication from the American Academy of Neurology’s
designation of Group One or Group Two [12] or (2) a migraine
preventive medication that had an FDA approval for prevention
of migraine before 30 September 2004. Exposure status was
determined after the initial migraine sample was identified.
Subjects were partitioned into one of three mutually exclusive
categories based on their use of prevention (Fig. 2). ‘Other
users’ were excluded to minimise potential biases associated
with the inclusion of prevalent users of migraine prevention in
an observational setting [25].
The remaining explanatory variables were based on the
conceptual framework [23]. Predisposing characteristics
included gender, age, geographic region and the branch of uni-
form service. Gender was a dichotomous variable with men as
the reference group. Age was modelled as a continuous vari-
able measured in years for each individual at the index date.
Geographic region was divided into 11 categories by TRI-
CARE region. The regions included ten areas inside the conti-
nental USA and one area for all persons residing overseas.
Branch of service corresponded to the Uniform Service of the
United States that the sponsor was assigned to while eligible
for care in the MHS. The variable included four categories
organised as follows: Army, Navy/Marine Corps, Air Force and
a category that included all the remaining branches of the
Uniformed Services.
Enabling characteristics included each subject’s beneficiary
category and preference for non-military pharmacy services.
Beneficiary category referred to a TRICARE designation that
indicated how a patient was classified in the MHS. The variable
distinguished between active duty military personnel and all oth-
ers categories because subjects on active duty were required to
meet certain baseline health requirements and had first dollar
health care coverage (i.e., no deductibles, premiums or copay-
ments). The other enabling characteristic was a subject’s prefer-
ence for non-military pharmacy services measured as the per-
centage of all prescriptions filled outside of a military pharmacy
during the study period. It was deemed enabling because pre-
scriptions dispensed from non-military pharmacies required
copays ($3 for generic and $9 for brand) whereas military phar-
macies were free of charge if the product was on the facility’s
formulary. The reference group included subjects who had all
prescriptions filled at military pharmacies. The remaining indi-
viduals were split into two groups; one with fewer than 40% and
the other with 40% or more of their prescriptions from a non-
military pharmacy.
Fig. 1 Index date and study defined intervals
Pre-treatment Transitional Post-treatment
(180 days) (180 days) (180 days)
INDEX DATE
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Characteristics of need included pre-treatment measures of
comorbidity, migraine frequency, migraine-related health care
expenditures and receipt of care from a neurologist. Comorbidity
was measured as a continuous variable derived from the number
of unique medication classes dispensed during the pre-treatment
period. This method has been shown to be a simple and efficient
method for measuring comorbidity status and predicting health
care expenditures [26–28]. Migraine frequency was assessed by
measuring each subject’s utilisation of MSAM in defined daily
doses (DDD) [29–31]. The formal definition of this variable was
the amount of MSAM dispensed in DDDs during the pre-treat-
ment interval. The use of DDDs provided a standardised unit of
measurement to account for the various medication classes, drug
doses and routes of administration available with MSAM treat-
ment. Furthermore, it provided a proxy for headache frequency
because a single DDD was designed to reflect the average amount
of abortive medication required to treat a migraine headache [29].
Migraine-related outpatient expenditures were measured as a con-
tinuous variable during the pre-treatment period and neurologist
care was a dichotomous variable that indicated if an individual
had at least one encounter with a neurologist during the pre-treat-
ment period.
Data analysis
The statistical analysis included a descriptive investigation of
the study population stratified by exposure to daily migraine pre-
vention. Means with standard deviations were calculated for
continuous variables. All categorical variables were described as
counts and percentages. For comparisons of health plan spend-
ing, we created a matched sample based on a propensity score
[32]. The propensity score was a measure of the probability that
a patient was exposed to prevention determined from the
observed explanatory variables. Matching new and non-users of
prevention with similar propensity scores removed the bias due
to observed characteristics, allowing for a comparison of
migraine-related spending between the two groups.
Estimation of the propensity score was accomplished with
logistic regression to determine the probability of exposure to
prevention during the transitional interval for new and non-
users. Explanatory variables were included in the model based
on the Behavioural Model for Health Care Utilisation. Once the
propensity score had been estimated, a balanced sample was cre-
ated using caliper matching. The propensity score caliper was
defined as 60% of the pooled standard deviation of the estimat-
ed propensity score [33]. After randomly ordering observations,
the control subject with the closest propensity score in absolute
terms that fell within the pre-defined caliper of each treated sub-
ject’s propensity score was selected. This matching process
ensured more homogenous subject pairs than other more com-
monly used matching strategies such as nearest neighbour
matching.
Treated units were designated as unmatched and removed
from the sample if the process failed to identify at least one con-
trol subject within the caliper above. After running each treated
subject through the matching process, the effectiveness of the
procedure was assessed by comparing two-sample t-statistics and
standardised percent differences (di) among study covariates for
the two groups [34]. Absolute values of di less than 10% and non-
significant t-tests supported the assumption of balance between
the two groups [34]. After confirmation of covariate balance, the
association between exposure to daily migraine prevention and
resource utilisation was estimated by calculating the difference
between matched pairs for each study endpoint. The mean differ-
ence between the two study cohorts represented the average treat-
ment effect of daily migraine prevention among the treated sub-
jects. Standard errors and 95% confidence intervals for the
matched sample were computed using a bootstrap with 250 repli-
cations. The propensity score, the matched sample and the aver-
age treatment effects were estimated with the PSMATCH2 mod-
ule for STATA 9.0 [35].
Results
The migraine sample population contained 3762 subjects.
This included 1144 new users and 2618 non-users of daily
migraine prevention. The population characteristics for
the full and matched sample are summarised in Table 1.
Subjects in the full sample were predominately female,
classified as other than active duty, with an average age of
36 years. The majority of the migraine population was
located within the continental USA and 10% resided over-
seas. Subjects received, on average, 4 DDDs per month of
MSAM during the pre-treatment interval. Eighteen per-
cent of study subjects in the full sample had at least one
encounter with a neurologist during the pre-treatment
period. Unadjusted expenditures for migraine-related out-
patient care in the full sample were estimated at $125.35
per member per month, driven primarily by spending on
prescription medication (51%) followed closely by non-
emergent ambulatory care (40%).
Table 2 summarises the degree of covariate imbalance
between the two study cohorts prior to matching for the
full sample. Subjects exposed to prevention (i.e., new
users) showed evidence of pre-existing differences for
several characteristics compared to the reference group of
non-users. Caliper matching on the propensity score iden-
tified a match for 997 new users (87%) of prevention. The
unmatched new users showed evidence of greater depen-
dence on migraine-specific abortive treatment, consumed
more outpatient health resources, had higher comorbidity
scores and were more likely to receive care from a neu-
rologist than the matched new users of prevention.
After matching, the results confirmed that new and
non-users of prevention had balanced distributions of the
study explanatory variables. Relative reductions in stan-
dardised percent differences ranged from 15% to 96% and
no statistical evidence of a difference was detected for
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study covariates among the matched sample of 1994
patients (Table 2). In addition, the mean predicted proba-
bilities (i.e., the average propensity score) to undergo
treatment with daily migraine prevention before matching
was reduced to within one percentage point after match-
ing, indicating a high degree of balance among observed
characteristics for the two study groups (Table 2).
Table 3 reports utilisation for new and non-users of pre-
vention obtained from the matched sample, with results
reported in US dollars. The table compares post-treatment
spending (upper half) and the difference between post-
treatment and transitional spending (lower half) for each
study endpoint. When evaluating post-treatment spending
alone, the results showed that new users spent more for
migraine-related outpatient care during the post-treatment
interval than the matched non-users did ($534.29, 95% CI
$407.60, $660.97). The largest differences were observed
with non-emergent ambulatory care expenditures followed
by spending for potentially and definitely migraine-related
prescription medication (Table 3).
Comparing the change in expenditures from the transi-
tional to post-treatment interval suggested that subjects
exposed to prevention experienced greater declines in
migraine-related outpatient spending than did the refer-
ence group of non-users over the same time period
(–$419.28, 95% CI –$539.39, –$299.18). This decrease
was predominately attributable to a reduction in spending
for non-emergent outpatient care (Table 3). Spending on
definitely migraine-related prescription medication also
decreased at a greater rate among new users of daily
migraine prevention compared to the reference group of
non-users. The only category of spending that showed evi-
dence of an increase in the treatment group relative to the
comparison group was potentially migraine-related pre-
scription medication, but the result was not statistically
significant (Table 3).
Discussion
This study offers additional insight into the association
between the initiation of migraine prevention and its
effect on ambulatory health care utilisation. The initial
assessment of health plan spending suggested that expo-
sure to prevention was associated with higher rates of
spending during the post-treatment interval compared to
the reference group of migraineurs receiving acute treat-
ment alone. One explanation for this result is that, despite
attempts to control for variation in disease severity, unde-
tected differences remained between the two study
groups. Current treatment recommendations typically sug-
gest that prevention be reserved for patients with more
Table 1 Sample characteristics and unadjusted ambulatory health
care spending in the full and matched study cohorts
Characteristic, N (%)
Full Matched
Number of patients 3762 1,994
Age (in years)a 35.8 (11.8) 34.8 (11.5)
Female 3,057 (81) 1,579 (79)
Beneficiary Category 
Active Duty 1,040 (28) 613 (31)
Other 2,722 (72) 1,381 (69)
Branch of Service
Army 1,264 (34) 675 (34)
Air Force 1,113 (29) 589 (30)
Navy/Marine 1305 (35) 685 (34)
Other 80 (2) 45 (2)
Geographic Region 
Northeast 358 (10) 164 (8)
Mid-Atlantic 652 (17) 363 (18)
Southeast 457 (12) 233 (12)
Gulf South 320 (9) 147 (7)
Heartland 217 (6) 137 (7)
Southwest 358 (10) 192 (10)
Central 569 (15) 296 (15)
Southern California 228 (6) 118 (6)
Golden Gate 87 (2) 61 (3)
Northwest 144 (4) 82 (4)
Overseas 372 (10) 201 (10)
Prescription Service 
MTF Only 1,453 (39) 726 (36)
Low Retail 1,091 (29) 661 (33)
High Retail 1,218 (32) 607 (30)
MSAM Use (in DDDs)a,b 3.8 (5.9) 4 (6.3)
Comorbidity (in unique 8.7 (6) 9.8 (5.9) 
prescriptions)a,c
Neurologist Carec 660 (18) 441 (22)
Migraine Related Expendituresa,b,d
Definitely Migraine 33.84 (68.55) 35.75 (70.77)
Related Medication
Potentially Migraine 30.20 (71.80) 36.10 (82.40) 
Related Medication
Non Emergent Ambulatory 50.63 (92.89) 61.56 (95.94)
Care
Emergency Room Care 10.68 (40.79) 12.44 (41.44)
Total Ambulatory Care 125.35 (175.84) 145.85 (175.20)
MTF, military treatment facility; amean (SD); bvalue reported as per
member per month; ccharacteristic determined from pre-treatment
interval only; dexpenditures measured in unadjusted US dollars
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debilitating headaches [12, 13]. Use of MSAM provided
indirect evidence that this recommendation was being fol-
lowed during the analysis. New users, on average,
received more abortive medication before exposure to
prevention than did the reference group of non-users, sug-
gesting that new users also experienced more frequent
migraines. Although we matched subjects on baseline use
of MSAM, it is unlikely that this variable was able to cap-
ture all aspects of migraine disease severity. Thus, resid-
ual confounding could explain why subjects exposed to
daily migraine prevention experienced higher rates of
health care utilisation on average (i.e., new users suffered
from greater migraine-related morbidity than did the ref-
erence group of non-users).
Based on this conclusion, it seems that exposure to
prevention leads to greater health care utilisation, a
counter-intuitive finding if prevention effectively reduces
the frequency and severity of migraine headaches. An
evaluation of the change in utilisation over time from the
transitional to post-treatment period provided more
insight into the likelihood of this association [36]. After
comparing the change in resource use over time, the
results showed that exposure to prevention was associated
with greater declines in migraine-related outpatient spend-
ing than what might have been expected if the new users
had not been exposed to treatment. The biggest changes
were observed for non-emergent outpatient care expendi-
tures, followed closely by spending on definitely
migraine-related prescription medication. Together, these
two categories were responsible for roughly 91% of the
Table 2 Covariate balance before and after caliper matching on select characteristics
di percent reduction
Characteristic Sample Xt Xc di Sig.
Age Unmatched 34.5 36.4 –16.5 ***
Matched 34.9 34.8 1.0 93.8 ns
Female Unmatched 0.781 0.827 –11.6 ***
Matched 0.793 0.791 0.5 95.6 ns
Beneficiary Category Unmatched 0.324 0.256 15.2 ***
Active Duty Matched 0.304 0.311 –1.6 89.8 ns
Prescription Service Unmatched 0.358 0.399 –8.5 **
MTF Only Matched 0.368 0.358 2.1 75.7 ns
Low Retail Unmatched 0.363 0.258 22.7 ***
Matched 0.326 0.339 –2.8 87.5 ns
High Retail Unmatched 0.280 0.343 –13.7 ***
Matched 0.306 0.303 0.7 95.2 ns
Pre-Treatment Comorbidity Unmatched 11.069 7.668 55.9 ***
Matched 9.775 9.894 –1.9 96.5 ns
Pre-Treatment Spending (ln) Unmatched 4.788 4.521 10.2 **
Matched 4.710 4.767 –2.2 78.6 ns
Pre-Treatment MSAM Use Unmatched 16.407 15.799 1.4 ns
Matched 16.323 15.804 1.2 14.6 ns
Neurologist Care Unmatched 0.288 0.126 40.9 ***
Matched 0.213 0.229 –4 90.1 ns
Propensity Score Unmatched 0.390 0.267 76.3 ***
Matched 0.341 0.349 –4.6 94 ns
Geographic region and branch of service are not reported in the table but were part of the model specification and balanced after matching. di,
standardised percent difference; Xt, new users covariate mean; Xc, non-users covariate mean; Sig., statistical significance; ns, not significant.
*p<0.05; **p<0.01; ***p<0.001, determined by a t-test
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reduction in health care utilisation.
This conclusion is supported by earlier work arguing
that prevention reduces the use of other migraine media-
tions as well as visits to physicians and the emergency
room [17]. The results from the current study were able to
address some previous criticisms. Incorporating a refer-
ence group of non-users matched on all observable char-
acteristics increased the strength of study conclusions to
threats against validity [19]. In addition, this study includ-
ed the costs of daily migraine prevention during the analy-
sis. Despite the differences in methodology, the qualita-
tive conclusions from this and the previous study [17] are
very similar.
The seemingly divergent answers reported in this
paper can be explained by the treatment of the dependent
variable and the type of question addressed. Comparison
of post-treatment outcomes only answered the question of
whether two identical patients prior to treatment would
consume differing amounts of health care after one patient
initiated treatment. However, this assumption of equality
was unrealistic given the constraints of the observational
design. As a result, those exposed to prevention appeared
to consume more resources than the reference group.
Modelling the change in utilisation over time after the ini-
tiation of treatment attempted to adjust for the pre-exist-
ing differences. The assumption was that the change in the
reference group provided an estimate of the change that
would have occurred in the treated group had they not
been given treatment. This method can explain why new
users were more costly than the reference group but still
managed to realise some cost-savings for the health plan
after initiation of daily migraine prevention.
The results from this study should be considered in
context of its limitations. First, we were unable to control
treatment assignment, which is a common limitation of
retrospective claims analyses. As a result, it is possible
that the reported treatment effects were due to unobserved
characteristics rather than exposure to daily migraine pre-
vention. Another important limitation of the study was the
absence of some important explanatory variables known
to influence health care utilisation. Where possible, the
study employed proxy measures for these unobserved
variables. Still, collection of extra data would enhance our
understanding of how a patient decides to use health care
resources for migraine.
This study excluded indirect costs that are known to be
a significant burden in migraine. In addition, generalis-
ability of the study results to populations beyond the
Military Health System is another limitation. The descrip-
tive data about subjects with migraine in the military sys-
tem showed some similarities with previous epidemiolog-
ical research [37]. However, other unique aspects of mili-
tary medicine may have influenced the patients’ response
to migraine prevention. Finally, errors in coding are prob-
lematic and difficult to assess in claims data. The assump-
tion was made that military data were accurate because
there are penalties for over-reporting care and under-
reporting would adversely affect manpower authorisation
or revenue in the facilities studied. In addition, several
quality checks (i.e., missing or out of range values) were
performed during the data analysis to look for any unusu-
al observations. The results suggested that the data were
Table 3 Comparison of ambulatory health care spending for matched study cohorts stratified by specification of the dependent variable
Utilization Estimates
Specification of dependent variable New User Non User ATT 95% CI1
Post-treatment interval spending only
Definitely migraine related prescription expenditures 266.57 171.82 94.75 54.94,134.56
Potentially migraine related prescription expenditures 334.74 198.31 136.43 76.56,196.30
Non-emergent ambulatory care expenditures 447.51 182.99 264.51 191.72, 337.30
Emergency room expenditures 81.08 42.49 38.59 6.69, 70.48
Total migraine related outpatient expenditures 1,129.89 595.61 534.29 407.60, 660.97
Post-treatment and transitional spending difference
Definitely migraine related prescription expenditures –87.94 –17.72 –70.22 –110.18, –42.15
Potentially migraine related prescription expenditures 29.03 13.85 15.28 –27.77, 58.33
Non-emergent ambulatory care expenditures –388.19 –68.71 –319.48 –403.75, –235.23
Emergency room expenditures –55.74 –16.83 –38.91 –78.51, 0.69
Total migraine related outpatient expenditures –502.74 –83.46 –419.28 –539.39, –299.18
The measures of effect were calculated from the matched sample (N=1994) and measured in unadjusted US dollars. ATT, average treatment effect
on the treated calculated as the difference between new and non-user utilisation estimates; Rx, prescription. 195% confidence intervals for the dif-
ference were computed using a bootstrap with 250 replications
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appropriate for use during the analysis.
In conclusion, the results of this study suggest that expo-
sure to daily migraine prevention did affect ambulatory
health care utilisation in the Military Health System com-
pared to a reference group of patients receiving acute
migraine treatment alone. Treatment with preventive agents
resulted in lower rates of utilisation relative to what new
users of prevention would have consumed in the absence of
treatment. As a result, the value of prevention appeared to
extend beyond just clinical improvement to include econom-
ic benefits as well. While the use of prevention remains a
patient-specific decision, only a small fraction of migraineurs
who could benefit from prevention in the USA are actually
receiving it [37]. Increasing the appropriate use of this treat-
ment will require that health care providers take the lead in
identification of appropriate candidates for prevention.
Furthermore, health plans should encourage candid discus-
sions between health care providers and patients that account
for individual preferences and focus on the benefits and risks
of preventive treatment. These modest improvements are a
first step toward bettering medical care for patients with
migraine and increasing appropriate utilisation of daily
migraine prevention.
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